ALMKT Stock Overview
Mauna Kea Technologies SA develops and markets medical devices in Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Mauna Kea Technologies SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.38 |
| 52 Week High | €0.77 |
| 52 Week Low | €0.34 |
| Beta | 1.38 |
| 1 Month Change | 5.12% |
| 3 Month Change | -21.10% |
| 1 Year Change | -31.00% |
| 3 Year Change | -72.85% |
| 5 Year Change | -78.31% |
| Change since IPO | -97.05% |
Recent News & Updates
Shareholder Returns
| ALMKT | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -3.7% | 1.6% | 1.2% |
| 1Y | -31.0% | 11.5% | 4.0% |
Return vs Industry: ALMKT underperformed the French Medical Equipment industry which returned 11.5% over the past year.
Return vs Market: ALMKT underperformed the French Market which returned 4% over the past year.
Price Volatility
| ALMKT volatility | |
|---|---|
| ALMKT Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALMKT's share price has been volatile over the past 3 months.
Volatility Over Time: ALMKT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 67 | Sacha Loiseau | www.maunakeatech.com |
Mauna Kea Technologies SA develops and markets medical devices in Europe and internationally. The company offers range of medical devices, which includes gastroenterology, pulmonology, urology, and drug development. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions.
Mauna Kea Technologies SA Fundamentals Summary
| ALMKT fundamental statistics | |
|---|---|
| Market cap | €23.36m |
| Earnings (TTM) | -€2.17m |
| Revenue (TTM) | €11.54m |
2.0x
P/S Ratio-10.8x
P/E RatioIs ALMKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALMKT income statement (TTM) | |
|---|---|
| Revenue | €11.54m |
| Cost of Revenue | €1.89m |
| Gross Profit | €9.66m |
| Other Expenses | €11.83m |
| Earnings | -€2.17m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 26, 2024
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 83.66% |
| Net Profit Margin | -18.79% |
| Debt/Equity Ratio | -176.5% |
How did ALMKT perform over the long term?
See historical performance and comparison